These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 8520516)
21. Correction of iron-deficient erythropoiesis in the treatment of anemia of chronic disease with recombinant human erythropoietin. Arndt U; Kaltwasser JP; Gottschalk R; Hoelzer D; Möller B Ann Hematol; 2005 Mar; 84(3):159-66. PubMed ID: 15565327 [TBL] [Abstract][Full Text] [Related]
22. Is erythropoietin treatment safe and effective in myeloma patients receiving hemodialysis? Caillette A; Barreto S; Gimenez E; Labeeuw M; Zech P Clin Nephrol; 1993 Sep; 40(3):176-8. PubMed ID: 8403574 [TBL] [Abstract][Full Text] [Related]
23. Prediction of response to recombinant human erythropoietin (rHuEpo) in anemia of malignancy. Cazzola M; Ponchio L; Pedrotti C; Farina G; Cerani P; Lucotti C; Novella A; Rovati A; Bergamaschi G; Beguin Y Haematologica; 1996; 81(5):434-41. PubMed ID: 8952157 [TBL] [Abstract][Full Text] [Related]
24. How erythropoietin affects bone marrow of uremic patients. Sikole A; Stojanovic A; Polenakovic M; Petrusevska G; Sadikario S; Saso R; Jovanovski M Am J Nephrol; 1997; 17(2):128-36. PubMed ID: 9096443 [TBL] [Abstract][Full Text] [Related]
25. Erythropoietin treatment in advanced multiple myeloma is associated with improved immunological functions: could it be beneficial in early disease? Prutchi-Sagiv S; Golishevsky N; Oster HS; Katz O; Cohen A; Naparstek E; Neumann D; Mittelman M Br J Haematol; 2006 Dec; 135(5):660-72. PubMed ID: 17107348 [TBL] [Abstract][Full Text] [Related]
26. Effect of low dose recombinant human omega erythropoietin (rHuEPO) on anaemia in patients on hemodialysis. Acharya VN; Sinha DK; Almeida AF; Pathare AV J Assoc Physicians India; 1995 Aug; 43(8):539-42. PubMed ID: 8772973 [TBL] [Abstract][Full Text] [Related]
28. Improvement of anemia in W/WV mice by recombinant human erythropoietin (rHuEPO) mediated through EPO receptors with lowered affinity. Kabaya K; Akiyama H; Nishi N; Misaizu T; Okada Y; Kawagishi M; Amano K; Kusaka M; Seki M; Uzumaki H Life Sci; 1995; 57(11):1067-76. PubMed ID: 7658914 [TBL] [Abstract][Full Text] [Related]
29. Recombinant human erythropoietin in the treatment of multiple myeloma-associated anemia. Mittelman M; Zeidman A; Fradin Z; Magazanik A; Lewinski UH; Cohen A Acta Haematol; 1997; 98(4):204-10. PubMed ID: 9401498 [TBL] [Abstract][Full Text] [Related]
30. Erythropoiesis after kidney transplantation: the role of erythropoietin, burst promoting activity and early erythroid progenitor cells. Lezaic V; Biljanovic-Paunovic L; Pavlovic-Kentera V; Djukanovic L Eur J Med Res; 2001 Jan; 6(1):27-32. PubMed ID: 11313188 [TBL] [Abstract][Full Text] [Related]
31. Erythropoietin and chronic lymphocytic leukemia. Mauro FR; Gentile M; Foa R Rev Clin Exp Hematol; 2002; Suppl 1():21-31. PubMed ID: 12735212 [TBL] [Abstract][Full Text] [Related]
32. Erythropoietin has an anti-myeloma effect - a hypothesis based on a clinical observation supported by animal studies. Mittelman M; Zeidman A; Kanter P; Katz O; Oster H; Rund D; Neumann D Eur J Haematol; 2004 Mar; 72(3):155-65. PubMed ID: 14962233 [TBL] [Abstract][Full Text] [Related]
33. Erythropoietic effects of triiodothyronine on the anemia of renal failure in rats: comparative studies with testosterone and erythropoietin. Malgor LA; Barrios L; de Albarenque ME; Verges E; de Markowsky EE; Montiel E; Mussin SM Exp Hematol; 1986 May; 14(4):250-6. PubMed ID: 3699108 [TBL] [Abstract][Full Text] [Related]
34. Prediction of response to treatment with recombinant human erythropoietin in anaemia associated with cancer. Beguin Y Med Oncol; 1998 Aug; 15 Suppl 1():S38-46. PubMed ID: 9785336 [TBL] [Abstract][Full Text] [Related]
35. rHuEPO and treatment outcomes: the preclinical experience. Ludwig H Oncologist; 2004; 9 Suppl 5():48-54. PubMed ID: 15591422 [TBL] [Abstract][Full Text] [Related]
36. Treatment of MDS patients with recombinant human erythropoietin and the role of GSTs. Tsabouri SE; Georgiou I; Katsaraki A; Bourantas KL J Exp Clin Cancer Res; 2004 Sep; 23(3):417-24. PubMed ID: 15595630 [TBL] [Abstract][Full Text] [Related]
37. Bone marrow infiltration by multiple myeloma causes anemia by reversible disruption of erythropoiesis. Bouchnita A; Eymard N; Moyo TK; Koury MJ; Volpert V Am J Hematol; 2016 Jun; 91(4):371-8. PubMed ID: 26749142 [TBL] [Abstract][Full Text] [Related]
38. Prediction of the responsiveness to treatment with erythropoiesis-stimulating factors: a prospective clinical study in patients with solid tumors. Steinmetz T; Hellmich M; Neise M; Aldaud A; Lerchenmüller C; Tsamaloukas A; Fandel F; Weiligmann C; Totzke U; Schmitz S Oncologist; 2007 Jun; 12(6):748-55. PubMed ID: 17602064 [TBL] [Abstract][Full Text] [Related]
39. Recombinant human erythropoietin therapy is very effective after an autologous peripheral blood stem cell transplant when started soon after engraftment. Baron F; Frère P; Fillet G; Beguin Y Clin Cancer Res; 2003 Nov; 9(15):5566-72. PubMed ID: 14654537 [TBL] [Abstract][Full Text] [Related]
40. Treatment of the anemia of multiple myeloma: the role of recombinant human erythropoietin. Barlogie B Semin Hematol; 1993 Oct; 30(4 Suppl 6):25-7. PubMed ID: 8153675 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]